Literature DB >> 24588012

Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study.

Christopher J Hoffmann, Salome Charalambous, Alison D Grant, Lynn Morris, Gavin J Churchyard, Richard E Chaisson.   

Abstract

Adherence interventions are a recommended strategy to salvage failing antiretroviral therapy without regimen change. We assessed the durability of resuppression when using this approach. Of 300 patients who resuppressed on the same regimen (41% of all those with virologic failure), 148 (45%) remained suppressed during follow-up for a median of 2.4 years (interquartile range [IQR]: 1.1, 4.0). Resuppression can be durable following viraemia without a switch in antiretroviral therapy regimen.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24588012      PMCID： PMC4070658          DOI： 10.1111/tmi.12237

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN： 1360-2276            Impact factor:   2.622


  19 in total

Review 1.  Viral load monitoring as a tool to reinforce adherence: a systematic review.

Authors:  Kimberly Bonner; Alyssa Mezochow; Teri Roberts; Nathan Ford; Jennifer Cohn
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

2.  Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Authors:  David Rey; Magali Krebs; Marialuisa Partisani; Georgette Hess; Christine Cheneau; Michèle Priester; Claudine Bernard-Henry; Erik de Mautort; Jean-Marie Lang
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

3.  HIV viral load monitoring in resource-limited regions: optional or necessary?

Authors:  Alexandra Calmy; Nathan Ford; Bernard Hirschel; Steven J Reynolds; Lut Lynen; Eric Goemaere; Felipe Garcia de la Vega; Luc Perrin; William Rodriguez
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

4.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

Authors:  Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

5.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Authors:  Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

6.  Impact of a modified directly administered antiretroviral treatment intervention on virological outcome in HIV-infected patients treated in Burkina Faso and Mali.

Authors:  C M Pirkle; C Boileau; V-K Nguyen; N Machouf; S Ag-Aboubacrine; P A Niamba; J Drabo; S Koala; C Tremblay; S Rashed
Journal:  HIV Med       Date:  2009-03       Impact factor: 3.180

7.  Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.

Authors:  Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood
Journal:  Antivir Ther       Date:  2007

8.  Use of Self-Reported Adherence and Keeping Clinic Appointments as Predictors of Viremia in Routine HIV Care in the Gambia.

Authors:  Kevin Peterson; Joris Menten; Ingrid Peterson; Toyin Togun; Uduak Okomo; Francis Oko; Tumani Corrah; Assan Jaye; Robert Colebunders
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-08-30

9.  Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome.

Authors:  Victoria Johnston; Katherine Fielding; Salome Charalambous; Mildred Mampho; Gavin Churchyard; Andrew Phillips; Alison D Grant
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

10.  Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Authors:  Zoe Fox; Andrew Phillips; Cal Cohen; Jacquie Neuhaus; John Baxter; Sean Emery; Bernard Hirschel; Kathy Huppler Hullsiek; Christoph Stephan; Jens Lundgren
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177
View more
  8 in total

1.  CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.

Authors:  Christopher J Hoffmann; Jean Maritz; Gert U van Zyl
Journal:  Trop Med Int Health       Date:  2015-12-10       Impact factor: 2.622

2.  HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Authors:  Soo-Yon Rhee; Michael R Jordan; Elliot Raizes; Arlene Chua; Neil Parkin; Rami Kantor; Gert U Van Zyl; Irene Mukui; Mina C Hosseinipour; Lisa M Frenkel; Nicaise Ndembi; Raph L Hamers; Tobias F Rinke de Wit; Carole L Wallis; Ravindra K Gupta; Joseph Fokam; Clement Zeh; Jonathan M Schapiro; Sergio Carmona; David Katzenstein; Michele Tang; Avelin F Aghokeng; Tulio De Oliveira; Annemarie M J Wensing; Joel E Gallant; Mark A Wainberg; Douglas D Richman; Joseph E Fitzgibbon; Marco Schito; Silvia Bertagnolio; Chunfu Yang; Robert W Shafer
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

3.  Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.

Authors:  Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Loveleen Bansi-Matharu; Papa Salif Sow; Peter Ehrenkranz; Deborah Ford; Owen Mugurungi; Tsitsi Apollo; Joseph Murungu; David R Bangsberg; Paul Revill
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

4.  HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.

Authors:  Adriaan E Basson; Salome Charalambous; Christopher J Hoffmann; Lynn Morris
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

5.  HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Orrell; Zara Shubber; Tsitsi Apollo; Lara Vojnov
Journal:  J Int AIDS Soc       Date:  2019-11       Impact factor: 5.396

6.  Evaluating HIV Viral Rebound Among Persons on Suppressive Antiretroviral Treatment in the Era of "Undetectable Equals Untransmittable (U = U)".

Authors:  Sugi Min; Fizza S Gillani; Su Aung; Joseph M Garland; Curt G Beckwith
Journal:  Open Forum Infect Dis       Date:  2020-11-16       Impact factor: 3.835

Review 7.  HIV-1 drug resistance and resistance testing.

Authors:  Dana S Clutter; Michael R Jordan; Silvia Bertagnolio; Robert W Shafer
Journal:  Infect Genet Evol       Date:  2016-08-29       Impact factor: 3.342

8.  Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second-line switches in Swaziland.

Authors:  David Etoori; Iza Ciglenecki; Mpumelelo Ndlangamandla; Celeste G Edwards; Kiran Jobanputra; Munyaradzi Pasipamire; Gugu Maphalala; Chunfu Yang; Inoussa Zabsonre; Serge M Kabore; Javier Goiri; Roger Teck; Bernhard Kerschberger
Journal:  J Int AIDS Soc       Date:  2018-10       Impact factor: 5.396
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.